Risks and Benefits of Preexposure and Postexposure Smallpox Vaccination

Emerging Infectious Diseases

Volumn 9, Issue 11, 2003, Pages 1363-1370

  Meltzer, Martin I ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE;

CONFERENCE PAPER; CONTACT EXAMINATION; DECISION CRITERIA; DISEASE COURSE; DRUG EFFICACY; HEALTH CARE PERSONNEL; HUMAN; MEDICAL DECISION MAKING; POSTEXPOSURE VACCINATION; POSTVACCINAL ENCEPHALITIS; PREEXPOSURE VACCINATION; PROBABILITY; REVACCINATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SMALLPOX; STATISTICAL ANALYSIS; STATISTICAL MODEL; VACCINATION; VACCINATION REACTION; VACCINIA; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0242386563     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0911.030369     Document Type: Conference Paper

References (45)

1. Meltzer MI. Model 1. In: Institute of Medicine. Scientific and policy considerations in developing smallpox vaccination options: a workshop report. Washington: National Academies Press; 2002. p. 15-7.
2. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jaheling PB, et al. Smallpox as a biological weapon: medical and public health response. JAMA 1999;281:2127-37.
3. Meltzer MI, Damon I, Leduc JW, Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis 2001:7:959-69.
4. Alibek K. Biohazard. New York: Random House; 1999.
5. Neff JM. The case for abolishing routine childhood smallpox vaccination in the United States. Am J Epidemiol 1971;93:245-7.
6. Lane MJ, Goldstein J. Evaluation of 21st century risks of smallpox vaccination and policy options. Ann Intern Med 2003;138:488-93.
7. Bozzette SA, Boer R, Bhatnagar V, Brower JL, Keeler EB, Morton SC, et al. A model for a smallpox-vaccination policy. N Engl J Med 2003;348:416-25.
8. Bush's comments on his plan for smallpox vaccinations across the U.S. New York Times (late edition) 2002 Dec 14; Sect. A:12.
9. McKenna MAJ, Moscoso E. State vaccinations for smallpox begin. Atlanta Journal-Constitution 2003, Jan 30; Sect. A:3.
10. Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002;346:1323-5.
11. de Rugy V, Pena CV. Responding to the threat of smallpox bioterrorism: an ounce of prevention is best approach. Policy Analysis 2002;434:1-16.
12. Charen M. Bioterrorism defense plan unworkable. Atlanta Journal-Constitution 2002 Sept. 24; Sect. A:17.
13. Blendon RJ, DesRoches CM, Benson JM, Hermann MJ, Taylor-Clark K, Weldon KJ. The public and the smallpox threat. N Engl J Med 2003;348-54.
14. McKenna MAJ. Grady's workers won't be given smallpox shot yet. Atlanta Journal-Constitution 2002 Dec. 17; Sect. D:8.
15. McNeil DG Jr. Many balking at vaccination for smallpox. New York Times 2003 Feb 07; Sect. A:1.
16. McKenna MAJ. No vaccination for nations fear; unease hinders smallpox program. Atlanta Journal-Constitution 2003 Feb. 15; Sect. A:1, 5.
17. McDonald L, Calenza J. Flags raised over smallpox vaccine. Atlanta Journal-Constitution 2003 Feb 20; Sect. A:19.
18. Connolly C. Smallpox vaccine delay rejected. Atlanta Journal-Constitution 2003 Jan 17; Sect. A:3.
19. Pear R. Officials seek smallpox vaccine compensation fund. New York Times 2003 Mar 7; Sect. A:15
20. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968; national surveillance in the United States. N Engl J Med 1969;281:1201-8.
21. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970;122:303-9.
22. Fenner F, Henderson DA, Arita I, Jezek, Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization; 1988.
23. Rao AR. Smallpox. Bombay: Kothari Book Depot; 1972.
24. Dixon CW. Smallpox. London: J & A Churchill; 1962.
25. Centers for Disease Control and Prevention. Update: cardiac-related events during the civilian smallpox vaccination program-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:492-6.
26. Hanna W. Studies in smallpox and vaccination. Bristol, UK: Wright; 1913.
27. Mack TM. Smallpox into Europe, 1950-1971. J Infect Dis 1972;125:161-9.
28. McCarthy K, Downie AW, Bradley WH. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J Hyg 1958;56:466-78.
29. el-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990;161:446-8.
30. Chapman GB. Your money or your health: time preferences and trading money for health. Med Decis Making 2002;22:410-6.
31. Reeve AM. Vaccination against smallpox in the United States-a reevaluation of the risks and benefits. Journal of the Iowa Medical Society 1971;61:655-7.
32. Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am J Epidemiol 1971;93:238-40.
33. Centers for Disease Control. Public Health Service recommendations on smallpox vaccination. MMWR Morb Mortal Wkly Rep 1971;20:339.
34. Hospital statistics; 1999 edition. Chicago: Health Forum, American Hospital Association; 1999.
35. Pasko T, Seidman B. Physician characteristics and distribution in the US. 1999 edition. Chicago: American Medical Association; 1999.
36. Gani R, Leach S. Transmission potential of smallpox in contemporary populations. Nature 2001;414:748-51.
37. Heiner GG, Fatima N, McCrumb FR. A study of intrafamilial transmission of smallpox. Am J Epidemiol 1971;94:316-26.
38. Mack TM, Thomas DB, Ali A, Khan MM. Epidemiology of smallpox in West Pakistan. I. Acquired immunity and the distribution of the disease. Am J Epidemiol 1972;95:157-68.
39. Rao AR, Jacob ES, Kamalakshi S, Appaswamy S, Bradbury. Epidemiological studies in smallpox: a study of interfamilial transmission in a series of 254 infected families. Ind J Med Res 1968;56:1826-54.
40. Dixon CW. Smallpox in Tripolitania, 1946: an epidemiological and clinical study of 5000 cases, including trials of penicillin treatment. J Hyg 1946;46:351-77.
41. Ropeik D, Gray G. Risk. Boston: Houghton Mifflin Co.; 2002.
42. Corso PS, Hammitt JK, Graham JD. Valuing mortality-risk reduction: using visual aids to improve the validity of contingent valuation. J Risk Uncertainty 2001;23:165-84.
43. Rabin M, Thaler RH. Anomalies: risk aversion. J Econ Perspectives 2001;15:219-32.
44. Rabin, M. Psychology and economics. J Econ Lit 1998;36:11-46.
45. Ropeik D. What really scares us. Parade Magazine 2003 Mar 30;12-4.